Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Virbac
  6. Summary
    VIRP   FR0000031577

VIRBAC

(VIRP)
  Report
Real-time Quote. Real-time Euronext Paris - 09/23 11:35:24 am
387 EUR   +0.26%
09/16Virbac Sa Reports Earnings Results for the Half Year Ended June 30, 2021
CI
09/15VIRBAC : availability of half year report
AQ
09/15VIRBAC : Half yearly financial report
PU
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Real-time Quote. Real-time Euronext Paris
09/17/2021 09/20/2021 09/21/2021 09/22/2021 09/23/2021 Date
376.5(c) 372(c) 393.5(c) 386(c) 387 Last
15 471 4 671 7 841 8 012 4 306 Volume
+1.62% -1.20% +5.78% -1.91% +0.26% Change
More quotes
Estimated financial data (e)
Sales 2021 1 050 M 1 229 M 1 229 M
Net income 2021 103 M 121 M 121 M
Net cash position 2021 126 M 148 M 148 M
P/E ratio 2021 31,5x
Yield 2021 0,50%
Sales 2022 1 092 M 1 279 M 1 279 M
Net income 2022 109 M 128 M 128 M
Net cash position 2022 202 M 237 M 237 M
P/E ratio 2022 30,2x
Yield 2022 0,64%
Capitalization 3 257 M 3 823 M 3 813 M
EV / Sales 2021 2,98x
EV / Sales 2022 2,80x
Nbr of Employees 4 907
Free-Float 49,3%
More Financials
Company
Virbac SA is a France-based veterinarian pharmaceutical company that specializes in the development and production of vaccines and medicines for domestic animals and livestock. Its production centers are located in France, Australia, the United States, Mexico, Vietnam, Brazil and South Africa. Its development efforts focus mainly on formulating drugs designed to prevent or cure certain animal diseases. Its product... 
More about the company
Ratings of Virbac
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B-
More Ratings
All news about VIRBAC
09/16Virbac Sa Reports Earnings Results for the Half Year Ended June 30, 2021
CI
09/15VIRBAC : availability of half year report
AQ
09/15VIRBAC : Half yearly financial report
PU
09/15VIRBAC : Significant increase in operating profit from ordinary activities for the first h..
AQ
09/15Virbac SA Provides Revenue Guidance for the Year 2021
CI
09/13VIRBAC : Buys 15% Stake in Chile's Centrovet for $17.7 Million
MT
09/13VIRBAC : Aquaculture : Virbac strengthens its position in Centrovet
GL
09/13Virbac SA acquired an additional 15% stake in Centrovet group for $17.7 million.
CI
07/29VIRBAC : is a winner of the "France recovery industry” plan
PU
07/21GLOBAL MARKETS LIVE : Netflix, Novartis, Tesla, Autodesk, AMC...
07/20VIRBAC : 2021 second quarter consolidated sales
PU
07/20VIRBAC : Exceptional increase in revenue in the first half of 2021, with +21.3% at compara..
GL
07/20Virbac SA Announces Non-Audited Consolidated Revenue Results for the Second Quarter and..
CI
07/15SUSTAINABLE DEVELOPMENT : strengthened commitments!
PU
07/08VIRBAC : in the USA has completed the acquisition of iVet LLC a specialty petfood company
PU
More news
News in other languages on VIRBAC
09/17VIRBAC : Oddo relève son objectif de cours
09/16VIRBAC : Oddo relève son objectif de cours
09/16VIRBAC : atteint un nouveau record
09/16VIRBAC : MidCap Partners relève son objectif de cours
09/16AVIS D'ANALYSTES DU JOUR : Air France KLM, Eurofins, Infineon, Idorsia, Ab Inbev, Getlink,..
More news
Stock Trading Strategies
VIRBAC - 07/28
Good timing to anticipate a continuation of the trend
BUY
More Stock Trading Analysis
Chart VIRBAC
Duration : Period :
Virbac Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VIRBAC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Last Close Price 386,00 €
Average target price 381,38 €
Spread / Average Target -1,20%
EPS Revisions
Managers and Directors
Christian Karst Chief Executive Officer
Sébastien Huron Chairman-Management Board
Habib Ramdani Chief Financial Officer
Marie-Hélène Dick-Madelpuech Chairman-Supervisory Board
Philippe Gaston Henri Capron Independent Member-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
VIRBAC62.18%3 823
ZOETIS INC.21.66%95 429
ELANCO ANIMAL HEALTH INCORPORATED3.68%15 042
DECHRA PHARMACEUTICALS PLC53.62%7 835
JINYU BIO-TECHNOLOGY CO., LTD.-27.96%2 605
SWEDENCARE AB (PUBL)133.08%2 066